Results · Apr-Jun 2026 · filed 7 Aug 2026
Gujarat Terce Laboratories Q1 FY27 results
Sales fell 17% to ₹9 crore from ₹10.9 crore in Apr-Jun 2025.
Operating profit was −₹0.49 crore, an operating margin of −5.5% (down 5.3 points from a year ago).
The net loss widened to ₹0.18 crore from ₹0.04 crore.
Against Jan-Mar 2026: sales −21%, swings to a loss.
Apr-Jun 2026 vs a year ago
| ₹ crore | Apr-Jun 2026 | Apr-Jun 2025 | Change |
|---|---|---|---|
| Sales | 9.0 | 10.9 | −17% |
| Operating profit (EBITDA) | -0.5 | -0.0 | n/m |
| Operating margin | −5.5% | −0.2% | −5.3 pts |
| Net profit | -0.2 | -0.0 | loss widens |
Standalone figures. Margins & ratios change in percentage points (pts).
The last 7 quarters
Filings that week
- 8 Aug 2026Announcement under Regulation 30 (LODR)-Newspaper Publication
- 7 Aug 2026Board Meeting Outcome for Outcome Of The Board Meeting Held On 7 August 2026
- 7 Aug 2026Unaudited Standalone Financial Results Of The Company For The First Quarter Ended 30 June 2026
From the company's results filed on BSE (Standalone). Business numbers only. Education & analysis, not investment advice or a recommendation.